10-Q: BioAffinity Faces Going Concern Amidst Nasdaq Delisting Risk

BioAffinity Technologies reports increased net losses and significant liquidity challenges, raising substantial doubt about its ability to continue as a going concern, despite growth in its CyPath Lung diagnostic test revenue and new patent grants.

Summary

• Net loss for the six months ended June 30, 2025, increased to $6.7 million, up from $4.1 million in the same period of 2024.
• Consolidated revenue decreased by 35% to $3.1 million for the six months ended June 30, 2025, compared to $4.8 million in 2024, primarily due to discontinuing unprofitable pathology services.
• CyPath Lung testing revenue increased by 56% to $323,000 for the six months ended June 30, 2025, compared to $207,000 in 2024, with 390 tests delivered.
• Cash and cash equivalents stood at $802,835 as of June 30, 2025, and approximately $300,000 as of August 14, 2025, which is anticipated to be sufficient only through August 2025.
• The company has an accumulated deficit of $60.4 million as of June 30, 2025, and a working capital deficit of approximately $0.9 million.
• Nasdaq issued a notice of non-compliance due to the common stock bid price falling below $1.00 and stockholders' equity being below the $2.5 million minimum requirement, with the company requesting a hearing appeal.
• Recent capital raises include $3.25 million gross proceeds from a public offering in May 2025 and $990,000 gross proceeds from a private placement of Series B Convertible Preferred Stock in August 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including a going concern warning, increasing losses, and Nasdaq non-compliance. While there are positive developments in product adoption and intellectual property, these are overshadowed by the immediate and critical liquidity and listing risks.

Positives

• CyPath Lung testing revenue increased by 56% for the six months ended June 30, 2025, reaching $323,000, reflecting growing adoption of the diagnostic test.
• The company reaffirmed its forecast of 3X year-over-year revenues for CyPath Lung, indicating strong future growth expectations for its core product.
• Recent patient case studies highlight CyPath Lung's effectiveness in detecting Stage 1A lung cancer where other tests were indeterminate, demonstrating significant clinical utility and potential for improved patient outcomes.
• Dr. Gordon Downie, an experienced pulmonary medicine and clinical research expert, was appointed Chief Medical Officer, strengthening the management team.
• Multiple new patents were granted in the U.S., China, and Canada for novel cancer-killing compositions and methods for detecting lung disease, enhancing the company's intellectual property portfolio.
• Strategic actions to discontinue unprofitable pathology services are aimed at streamlining operations and focusing on higher-margin services like CyPath Lung.

Negatives

• Net loss significantly increased to $6.7 million for the six months ended June 30, 2025, compared to $4.1 million in the prior year, indicating worsening financial performance.
• Consolidated revenue decreased by 35% to $3.1 million for the six months ended June 30, 2025, primarily due to the discontinuation of unprofitable services, impacting overall top-line growth.
• The company's cash and cash equivalents of approximately $300,000 as of August 14, 2025, are only sufficient to fund operations through August 2025, highlighting severe liquidity constraints.
• An accumulated deficit of $60.4 million and a working capital deficit of approximately $0.9 million as of June 30, 2025, reflect a weak financial position.
• The company received a Nasdaq notice of non-compliance for both its minimum bid price ($1.00) and stockholders' equity ($2.5 million), posing a significant delisting risk.
• A $1.0 million loss was recorded on the remeasurement of warrant liabilities for the six months ended June 30, 2025, impacting profitability.
• Significant dilution from recent and planned capital raises, including the issuance of millions of new shares and warrants, will impact existing shareholders.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for at least the next twelve months due to recurring losses and insufficient cash resources.
• Failure to raise additional capital through equity or debt securities, strategic relationships, or grants could force the company to curtail or cease operations.
• The company is at risk of delisting from The Nasdaq Capital Market due to non-compliance with both the minimum bid price and stockholders' equity requirements.
• The company's future profitability is uncertain and depends on successful commercialization of diagnostic tests and therapeutic products, which are in preliminary phases.
• Dependence on third parties for clinical trials and regulatory approvals poses operational risks.
• The potential for results of pre-clinical and clinical trials to indicate diagnostic tests or therapeutic product candidates are unsafe or ineffective.
• Inability to obtain and maintain intellectual property protection or incurring substantial costs from IP lawsuits.
• Competition from existing and future therapies and diagnostic tests could impact market acceptance and revenue growth.
• The concentration of voting power (46.13%) by management could delay or prevent changes beneficial to other stockholders.

Future Outlook

The company anticipates needing to raise further capital through additional equity or debt securities, strategic relationships, or grants to support future operations, as current cash resources are only sufficient through August 2025. It expects to continue incurring significant operating losses for the foreseeable future. The company reaffirmed its forecast of 3X year-over-year revenues for CyPath Lung and intends to seek strategic partners for its therapeutic discoveries. Future plans include expanding commercialization efforts and advancing diagnostic tests through clinical trials.

Management Comments

• Management concludes that there is substantial doubt about the company's ability to continue as a going concern for a period of at least twelve months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements.
• Without funding from the proceeds of a capital raise or strategic relationship or grant, current cash resources are sufficient to continue operations through August 2025.
• The company reaffirmed its forecast of 3X year-over-year revenues for CyPath Lung.
• The company intends to seek strategic partners to develop our therapeutic discoveries which could result in broad-spectrum cancer treatments in the future.

Industry Context

The company operates in the highly competitive and regulated medical diagnostics and therapeutics industry, specifically focusing on noninvasive early detection of lung cancer and other lung diseases using advanced flow cytometry and AI. Its CyPath Lung test addresses a critical need in lung cancer, the leading cause of cancer-related deaths. The company is also expanding into diagnostics for asthma and COPD and developing broad-spectrum cancer treatments, positioning itself in high-growth areas of precision medicine. Operating as a laboratory developed test (LDT) under CAP/CLIA, it navigates a complex regulatory landscape with aspirations for FDA clearance and CE-marking in the EU.

Comparison to Industry Standards

• CyPath Lung's ability to detect Stage 1A lung cancer, which boasts a 95% 10-year survival rate, significantly outperforms the current overall 5-year survival rate of 26% for lung cancer, suggesting a strong clinical advantage over traditional diagnostic pathways.
• Patient case studies demonstrate CyPath Lung's efficacy in identifying cancer where conventional imaging and competitive serum tests were indeterminate, indicating a potential for superior diagnostic accuracy in complex cases compared to existing market offerings.
• While the company's CyPath Lung revenue is growing, its overall consolidated revenue decline due to strategic divestitures of unprofitable services indicates a restructuring phase rather than broad market expansion, making direct financial comparisons to established, diversified industry players challenging without specific segment data.
• The company's reliance on capital raises and its going concern warning are not uncommon for early-stage biotech and diagnostic companies, but the current liquidity position and Nasdaq non-compliance are more severe than typical industry benchmarks for publicly traded entities.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various disputes and litigation matters that arise in the ordinary course of business, but currently has no material pending legal proceedings.

Stakeholder Impact

• **Shareholders**: Face significant dilution from recent and planned capital raises, substantial risk of Nasdaq delisting, and potential loss of investment due to going concern issues. Management's concentrated ownership (46.13%) may limit other shareholders' influence.
• **Employees**: The company's financial instability and cost-cutting measures could impact job security and compensation, though the addition of new personnel for CyPath Lung sales suggests some growth areas.
• **Customers (Physicians/Patients)**: Continued availability of CyPath Lung and other diagnostic services depends on the company's ability to secure funding and maintain operations. Positive case studies suggest high clinical value for patients.
• **Creditors**: Face increased risk due to the company's liquidity challenges and going concern warning, potentially impacting the recoverability of debts.
• **Suppliers**: May face payment delays or reduced orders if the company's financial situation deteriorates further.

Next Steps

• Raise further capital through equity or debt securities, strategic relationships, or grants to support future operations.
• Continue efforts to regain compliance with Nasdaq listing requirements, including the bid price and stockholders' equity rules, and await the outcome of the hearing appeal.
• Advance development of the flow cytometry platform for diagnostic tests targeting Chronic Obstructive Pulmonary Disease (COPD) and asthma.
• Continue research and development for the broad-spectrum cancer therapeutic approach, with initial application for topical treatment of squamous cell skin cancer.
• Seek strategic partners to develop therapeutic discoveries.
• Expand commercialization efforts for CyPath Lung and other high-margin services.

Key Dates

Recommendation

The company faces immediate and severe financial distress, evidenced by a stated 'substantial doubt' about its ability to continue as a going concern, cash reserves only lasting through August 2025, and a significant increase in net losses. Furthermore, the company is non-compliant with Nasdaq listing rules for both minimum bid price and stockholders' equity, leading to a high risk of delisting. While there are positive developments in CyPath Lung's clinical adoption and new patent grants, these are entirely overshadowed by the critical liquidity crisis and the imminent threat to its public listing. The ongoing need for dilutive capital raises further erodes shareholder value. A seasoned investor would recognize these as fundamental red flags indicating extreme risk and advise divesting.

Keywords

Lung Cancer Diagnosis, CyPath Lung, Flow Cytometry, AI Diagnostics, Biotechnology, Medical Devices, Oncology, Diagnostics, SEC Filing, 10-Q, Going Concern, Nasdaq Delisting, Capital Raise, Clinical Trials, Patents